Cargando…
Loss of circadian clock gene expression is associated with tumor progression in breast cancer
Several studies suggest a link between circadian rhythm disturbances and tumorigenesis. However, the association between circadian clock genes and prognosis in breast cancer has not been systematically studied. Therefore, we examined the expression of 17 clock components in tumors from 766 node-nega...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613905/ https://www.ncbi.nlm.nih.gov/pubmed/25485508 http://dx.doi.org/10.4161/15384101.2014.954454 |
_version_ | 1782396337575165952 |
---|---|
author | Cadenas, Cristina van de Sandt, Leonie Edlund, Karolina Lohr, Miriam Hellwig, Birte Marchan, Rosemarie Schmidt, Marcus Rahnenführer, Jörg Oster, Henrik Hengstler, Jan G |
author_facet | Cadenas, Cristina van de Sandt, Leonie Edlund, Karolina Lohr, Miriam Hellwig, Birte Marchan, Rosemarie Schmidt, Marcus Rahnenführer, Jörg Oster, Henrik Hengstler, Jan G |
author_sort | Cadenas, Cristina |
collection | PubMed |
description | Several studies suggest a link between circadian rhythm disturbances and tumorigenesis. However, the association between circadian clock genes and prognosis in breast cancer has not been systematically studied. Therefore, we examined the expression of 17 clock components in tumors from 766 node-negative breast cancer patients that were untreated in both neoadjuvant and adjuvant settings. In addition, their association with metastasis-free survival (MFS) and correlation to clinicopathological parameters were investigated. Aiming to estimate functionality of the clockwork, we studied clock gene expression relationships by correlation analysis. Higher expression of several clock genes (e.g., CLOCK, PER1, PER2, PER3, CRY2, NPAS2 and RORC) was found to be associated with longer MFS in univariate Cox regression analyses (HR<1 and FDR-adjusted P < 0.05). Stratification according to molecular subtype revealed prognostic relevance for PER1, PER3, CRY2 and NFIL3 in the ER+/HER2- subgroup, CLOCK and NPAS2 in the ER-/HER2- subtype, and ARNTL2 in HER2+ breast cancer. In the multivariate Cox model, only PER3 (HR = 0.66; P = 0.016) and RORC (HR = 0.42; P = 0.003) were found to be associated with survival outcome independent of established clinicopathological parameters. Pairwise correlations between functionally-related clock genes (e.g., PER2-PER3 and CRY2-PER3) were stronger in ER+, HER2- and low-grade carcinomas; whereas, weaker correlation coefficients were observed in ER- and HER2+ tumors, high-grade tumors and tumors that progressed to metastatic disease. In conclusion, loss of clock genes is associated with worse prognosis in breast cancer. Coordinated co-expression of clock genes, indicative of a functional circadian clock, is maintained in ER+, HER2-, low grade and non-metastasizing tumors but is compromised in more aggressive carcinomas. |
format | Online Article Text |
id | pubmed-4613905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-46139052015-11-02 Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cadenas, Cristina van de Sandt, Leonie Edlund, Karolina Lohr, Miriam Hellwig, Birte Marchan, Rosemarie Schmidt, Marcus Rahnenführer, Jörg Oster, Henrik Hengstler, Jan G Cell Cycle Reports Several studies suggest a link between circadian rhythm disturbances and tumorigenesis. However, the association between circadian clock genes and prognosis in breast cancer has not been systematically studied. Therefore, we examined the expression of 17 clock components in tumors from 766 node-negative breast cancer patients that were untreated in both neoadjuvant and adjuvant settings. In addition, their association with metastasis-free survival (MFS) and correlation to clinicopathological parameters were investigated. Aiming to estimate functionality of the clockwork, we studied clock gene expression relationships by correlation analysis. Higher expression of several clock genes (e.g., CLOCK, PER1, PER2, PER3, CRY2, NPAS2 and RORC) was found to be associated with longer MFS in univariate Cox regression analyses (HR<1 and FDR-adjusted P < 0.05). Stratification according to molecular subtype revealed prognostic relevance for PER1, PER3, CRY2 and NFIL3 in the ER+/HER2- subgroup, CLOCK and NPAS2 in the ER-/HER2- subtype, and ARNTL2 in HER2+ breast cancer. In the multivariate Cox model, only PER3 (HR = 0.66; P = 0.016) and RORC (HR = 0.42; P = 0.003) were found to be associated with survival outcome independent of established clinicopathological parameters. Pairwise correlations between functionally-related clock genes (e.g., PER2-PER3 and CRY2-PER3) were stronger in ER+, HER2- and low-grade carcinomas; whereas, weaker correlation coefficients were observed in ER- and HER2+ tumors, high-grade tumors and tumors that progressed to metastatic disease. In conclusion, loss of clock genes is associated with worse prognosis in breast cancer. Coordinated co-expression of clock genes, indicative of a functional circadian clock, is maintained in ER+, HER2-, low grade and non-metastasizing tumors but is compromised in more aggressive carcinomas. Taylor & Francis 2014-10-30 /pmc/articles/PMC4613905/ /pubmed/25485508 http://dx.doi.org/10.4161/15384101.2014.954454 Text en © 2014 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Reports Cadenas, Cristina van de Sandt, Leonie Edlund, Karolina Lohr, Miriam Hellwig, Birte Marchan, Rosemarie Schmidt, Marcus Rahnenführer, Jörg Oster, Henrik Hengstler, Jan G Loss of circadian clock gene expression is associated with tumor progression in breast cancer |
title | Loss of circadian clock gene expression is associated with tumor progression in breast cancer |
title_full | Loss of circadian clock gene expression is associated with tumor progression in breast cancer |
title_fullStr | Loss of circadian clock gene expression is associated with tumor progression in breast cancer |
title_full_unstemmed | Loss of circadian clock gene expression is associated with tumor progression in breast cancer |
title_short | Loss of circadian clock gene expression is associated with tumor progression in breast cancer |
title_sort | loss of circadian clock gene expression is associated with tumor progression in breast cancer |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613905/ https://www.ncbi.nlm.nih.gov/pubmed/25485508 http://dx.doi.org/10.4161/15384101.2014.954454 |
work_keys_str_mv | AT cadenascristina lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT vandesandtleonie lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT edlundkarolina lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT lohrmiriam lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT hellwigbirte lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT marchanrosemarie lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT schmidtmarcus lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT rahnenfuhrerjorg lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT osterhenrik lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer AT hengstlerjang lossofcircadianclockgeneexpressionisassociatedwithtumorprogressioninbreastcancer |